Roche has secured a definitive lead in autoimmune kidney disease with a Phase 3 win for Gazyva in primary membranous nephropathy, cementing its “deep B-cell depletion” moat in immunology. Meanwhile, Sanofi’s reported sweetened bid for Ocular Therapeutix signals a high-stakes pre-emptive move ahead of today’s binary Phase 3 data readout for wet AMD therapy AXPAXLI—a decision that could either validate or unravel the strategy entirely.
đź“… Today’s Agenda
Tue 2/17 (Today): Medtronic (MDT) Q3 FY26 Earnings — Watch Symplicity and PulseSelect adoption
Tue 2/17 (Today): Ocular Therapeutix (OCUL) SOL-1 Phase 3 Data — Binary outcome for wet AMD therapy
Tue 2/17 (Today): Disc Medicine (IRON) Investor Call (8am ET) — CRL response and APOLLO trial strategy
Tue 2/17–18: BioAsia 2026 (Hyderabad) — Novartis and Lilly manufacturing focus
Sat 2/21: Vanda (PDUFA) — FDA decision on Bysanti for bipolar I and schizophrenia
Top Story: Roche’s Gazyva Wins Phase 3 in Primary Membranous Nephropathy
What Happened: Roche announced that its Phase 3 MAJESTY study for Gazyva (obinutuzumab) in primary membranous nephropathy (PMN) met its primary endpoint, demonstrating significantly higher complete remission rates at 104 weeks compared to tacrolimus, the current standard of care.
Primary Membranous Nephropathy Background: PMN is an autoimmune kidney disease caused by the immune system attacking the glomerular filtration membrane, leading to massive protein loss in urine (nephrotic syndrome) and progressive kidney dysfunction. Approximately 12,000-15,000 new cases are diagnosed annually in the United States. Up to 30% of patients progress to kidney failure within a decade without effective treatment.
Current Standard of Care Limitations: Tacrolimus, a calcineurin inhibitor, suppresses the immune response broadly but does not address the underlying B-cell mediated pathology in PMN. Relapse rates after tacrolimus discontinuation exceed 50%, and the drug carries significant toxicity concerns including nephrotoxicity—problematic in a disease that already threatens kidney function.
Gazyva’s Mechanism: Obinutuzumab is a glycoengineered anti-CD20 monoclonal antibody that depletes B-cells more completely than rituximab (the first-generation anti-CD20). The glycoengineering enhances antibody-dependent cellular cytotoxicity, producing deeper and more durable B-cell depletion. In PMN, eliminating the B-cells that produce anti-PLA2R antibodies addresses the root cause rather than suppressing downstream inflammation.
Why This Win Is Strategically Significant:
PMN is the second major immunology win for Gazyva this year. Earlier in 2026, Roche reported positive REGENCY trial data in lupus nephritis—establishing Gazyva as a legitimate platform therapy across autoimmune kidney diseases.
The Tacrolimus Comparison Advantage: Unlike clinical trials that compare to placebo, the MAJESTY study measured against an active and commonly used therapy. Superiority over tacrolimus at 104 weeks is a clinically meaningful bar—not a surrogate endpoint—making this data highly defensible under FDA’s current evidentiary standards.
Complete Remission as Endpoint: Complete remission in PMN requires proteinuria reduction to near-normal levels (typically <0.3g/day) alongside preserved kidney function. This is a robust clinical outcome endpoint, not a biomarker surrogate—directly addressing the FDA’s current scrutiny of biomarker-only approvals.
Roche’s Broader Strategic Position:
Roche faces near-term pressure from biosimilar competition on several oncology assets including Rituxan (rituximab), Herceptin (trastuzumab), and Avastin (bevacizumab). The strategic pivot toward immunology and rare diseases with high evidentiary standards, premium pricing, and defensible mechanisms represents a coherent response to that pressure.
The Nephrology “Safe Haven” Thesis:
Kidney diseases remain largely insulated from pharmaceutical pricing pressures affecting larger markets like obesity and cardiovascular disease. The combination of: high unmet need, orphan-like patient populations, robust clinical endpoint requirements, and limited political visibility on drug pricing creates a favorable commercial environment.
Novartis atrasentan (endothelin receptor antagonist for IgA nephropathy) and now Roche Gazyva in PMN confirm that nephrology is producing durable, premium-priced approvals with limited competitive pressure.
Market Opportunity: PMN affects approximately 12,000-15,000 new patients annually in the U.S. with a prevalent population of roughly 50,000-60,000. At premium rare disease pricing ($50,000-100,000 annually), Gazyva’s PMN indication could generate $300-600 million at peak penetration of 30-40%. Combined with the lupus nephritis indication and potential future expansions (IgA nephropathy, ANCA vasculitis), the nephrology franchise could reach $1-1.5 billion.
Competitive Landscape:
- Rituximab (Roche’s own Rituxan, plus biosimilars): Current off-label use in PMN with less robust depletion than Gazyva
- Voclosporin (Aurinia): Approved for lupus nephritis, calcineurin inhibitor with better renal safety than tacrolimus
- Sparsentan (Travere): Approved for IgA nephropathy, different mechanism
Gazyva’s superior B-cell depletion profile and now head-to-head superiority data over tacrolimus positions it as the likely preferred option for physicians seeking complete remission.
Regulatory Timeline: With Phase 3 data in hand, Roche will likely file for PMN indication in the second half of 2026. FDA priority review is possible given unmet need. Approval in 2027 is achievable.
What to Watch: Full data publication with complete remission rates at specific time points, durability of response, safety profile details, and Roche’s pricing strategy for the PMN indication.
đźš© Contrarian Flag: Relapse Rate Questions
While complete remission at 104 weeks is meaningful, the critical question is durability after Gazyva discontinuation. If B-cell repletion leads to PMN relapse at rates similar to rituximab (30-50% within 2 years), the commercial case depends on repeat dosing cycles. This is clinically manageable but affects cost-effectiveness calculations.
Sanofi vs. Ocular Therapeutix: Pre-Emptive M&A or Desperate Bet?
What Happened: Reports emerged yesterday that Sanofi has submitted a revised, sweetened acquisition bid for Ocular Therapeutix, increasing from its rejected September 2025 offer of approximately $16/share to a range reportedly between $22-28/share. The timing—hours before Ocular’s Phase 3 SOL-1 data readout for AXPAXLI in wet age-related macular degeneration—has created a binary situation with significant implications.
AXPAXLI (Axitinib Implant) Background: AXPAXLI is a biodegradable intravitreal implant designed to deliver the anti-VEGF agent axitinib directly into the eye over an extended period. Unlike current wet AMD therapies (Eylea, Lucentis, Vabysmo) requiring injections every 4-12 weeks, AXPAXLI aims to provide durable anti-VEGF activity from a single implant placed in the eye’s vitreous cavity.
The SOL-1 Trial Design: The Phase 3 SOL-1 trial is evaluating AXPAXLI against Eylea (aflibercept 2mg) in treatment-naĂŻve wet AMD patients over 12 months. The primary endpoint is non-inferiority in visual acuity improvement, with secondary endpoints including injection burden reduction and extended treatment intervals.
Why the Timing Matters:
Sanofi’s decision to bid before the data reveals either high internal confidence or strategic desperation:
The Confidence Case:
- Sanofi has access to clinical investigators, conference presentations, or patient registry data suggesting strong SOL-1 results
- Pre-data acquisition avoids bidding war that successful results would trigger
- A 40-50% premium ($22-28 vs. $16 rejected) reflects expected post-data re-rating
The Desperation Case:
- Sanofi’s ophthalmology pipeline has significant gaps following Regeneron’s dominant Eylea franchise
- Pressure to deploy capital and show growth strategy
- Fear that Roche, Novartis, or AbbVie would outbid Sanofi post-positive data
- Management willing to pay certainty premium over waiting for clarity
The Wet AMD Market Context:
Wet AMD affects approximately 1.5 million U.S. patients with significant treatment burden. Current standard of care requires frequent intravitreal injections—a painful, logistically complex procedure many patients struggle to maintain. Injection burden is the single largest compliance challenge in retinal disease treatment.
If AXPAXLI achieves non-inferiority with 6-12 month dosing intervals:
- Dramatically reduces patient burden (2-3 injections/year vs. 6-12 currently)
- Ophthalmologist practices benefit from reduced procedure volume but maintained revenue
- Payer interest in long-acting solutions that improve adherence
- Premium pricing justified over standard injections
The Competitive Landscape:
Several companies are pursuing long-acting wet AMD therapies:
- Regeneron’s Eylea HD: Approved extended dosing (every 12-16 weeks for some patients)
- Roche/Genentech’s port delivery system (Ranibizumab): Implant requiring periodic refills, limited commercial uptake due to procedure complexity
- Apellis/Astellas’ Syfovre: Complement-targeted, different mechanism, different indication
- Various small molecules in development
AXPAXLI’s differentiation: Biodegradable implant (no removal required), axitinib mechanism potentially superior VEGF suppression, and true long-acting profile without repeated office procedures.
Today’s Binary Outcomes:
Bull Scenario: SOL-1 Shows Non-Inferiority
- AXPAXLI matches Eylea on visual acuity
- Demonstrates significant injection burden reduction
- Sanofi’s $22-28 bid likely accepted at or near top of range
- Sanofi captures premium wet AMD position for 2028+ launch
- Potential bidding war from other ophthalmology-focused acquirers
Bear Scenario: SOL-1 Misses Non-Inferiority
- AXPAXLI fails to maintain visual acuity at Eylea’s level
- Sanofi withdraws bid
- Ocular Therapeutix shares decline 50-70% to near-cash value
- Wet AMD program requires redesign or abandonment
What This Means for Sanofi:
Sanofi’s ophthalmology strategy has been building since entering retinal disease with Dupixent studies in thyroid eye disease and uveitis. A wet AMD asset would complete a comprehensive ophthalmology franchise. The failure scenario leaves Sanofi needing to redeploy capital into alternative ophthalmology plays, likely at less favorable prices.
What to Watch: SOL-1 data release (today), Ocular Therapeutix board response to the revised bid, and whether additional bidders emerge if data is positive.
Oncology & Corporate Developments
CStone Pharmaceuticals: Trispecific Antibody Enters Global Phase 2
What Happened: CStone Pharmaceuticals received FDA Investigational New Drug clearance for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, to advance into a global Phase 2 trial across nine solid tumor indications including non-small cell lung cancer and triple-negative breast cancer.
The Trispecific Concept: While bispecific antibodies (targeting two antigens simultaneously) are becoming established in oncology, trispecific antibodies represent the next frontier—simultaneously blocking three tumor-promoting pathways in a single molecule.
CS2009’s Target Rationale:
- PD-1 blockade: Releases T-cell brake (like pembrolizumab/nivolumab)
- VEGF blockade: Inhibits tumor blood vessel formation (like bevacizumab)
- CTLA-4 blockade: Provides second immune checkpoint release (like ipilimumab)
Current Combination Standard: The combination of PD-1 + VEGF + CTLA-4 blockade is already used in some cancers (e.g., Opdivo + Yervoy + bevacizumab in hepatocellular carcinoma), but requires three separate drugs with additive toxicity from each.
Trispecific Advantage: A single molecule targeting all three pathways could:
- Reduce systemic toxicity versus combination regimens
- Ensure co-localization at the tumor (all three mechanisms active at same site)
- Simplify dosing and administration
- Provide intellectual property protection for novel molecule
Competitive Context: Multiple companies are developing PD-1/VEGF bispecifics (Akeso, Sichuan Biokin, Summit Therapeutics), with some showing impressive efficacy. CS2009’s addition of CTLA-4 blockade represents incremental ambition that also adds development risk.
What to Watch: Phase 2 enrollment speed, early efficacy signals in NSCLC (most competitive and largest opportunity), and safety profile relative to combination regimens.
Aurobindo: Pomalidomide Generic Confirms Biosimilar Timeline Delay
What Happened: Aurobindo Pharma confirmed a Q4 2026 launch for its generic to Pomalyst (pomalidomide) in multiple myeloma, while simultaneously pushing its broader “biosimilar inflection” projection to FY2029—acknowledging that technical hurdles are protecting incumbent biologics longer than expected.
Multiple Myeloma Generic Opportunity: Pomalyst (pomalidomide) is a third-generation IMiD agent for multiple myeloma generating approximately $3+ billion annually. Generic entry will create competitive pricing pressure and revenue erosion for Bristol-Myers Squibb.
The Biosimilar Delay Signal: Aurobindo’s extension of its biosimilar inflection timeline to FY2029 reflects broader industry reality—developing biosimilars for complex biologics (monoclonal antibodies, ADCs, fusion proteins) requires more analytical work, clinical bridging studies, and manufacturing validation than initially projected.
Incumbent Protection Period: The additional 12-18 month runway for existing biologic brands before meaningful biosimilar competition:
- Provides revenue stability for companies like Regeneron (Eylea HD transition), Amgen, and AbbVie
- Allows pricing adjustments and patient transition programs
- Reduces near-term revenue headwinds from biosimilar erosion
Alkermes Completes Avadel Acquisition
What Happened: Alkermes completed its $2.37 billion acquisition of Avadel Pharmaceuticals, adding Lumryz (sodium oxybate for narcolepsy) to its portfolio.
Strategic Rationale: Alkermes has been building a sleep medicine presence alongside its central nervous system drug portfolio (Vivitrol for addiction, Lybalvi for schizophrenia). Lumryz provides:
- Immediate revenue stream from an approved, differentiated narcolepsy therapy
- Dosing advantage: Once-nightly formulation vs. twice-nightly competitor Xyrem
- Platform for broader CNS sleep medicine expansion
Market Dynamics: Narcolepsy affects approximately 200,000 Americans and is severely underdiagnosed. The sodium oxybate market generates approximately $2+ billion annually, and Lumryz’s once-nightly formulation addresses the primary patient complaint about existing therapy.
Alkem MedTech: Structural Heart Push via Occlutech Stake
What Happened: Alkem MedTech agreed to acquire a 55% stake in Occlutech for €99.4 million, targeting the structural heart market where Occlutech holds Europe’s second-largest position in minimally invasive cardiac implants.
Strategic Context: Structural heart disease—conditions requiring catheter-based repair of cardiac defects, valves, and septal abnormalities—is one of medtech’s fastest-growing segments. Occlutech specializes in devices for atrial septal defects, patent foramen ovale closure, and ventricular septal defects.
Geographic Opportunity: Occlutech’s strong European position provides entry into a regulated premium market. Combining with Alkem’s distribution capabilities and capital could accelerate U.S. regulatory clearances and market entry.
Policy & Public Health
HIPAA Compliance Deadline: Today
What Is Required: Today is the final deadline for healthcare providers and health plans to update their Notice of Privacy Practices (NPP) to comply with revised HIPAA regulations under 42 CFR Part 2, which strengthens protections for Substance Use Disorder (SUD) treatment records.
What Changed: The updated rules limit how SUD-related healthcare records can be shared without patient consent, even within treating provider networks. The intent is to reduce stigma barriers to SUD treatment by ensuring patients that seeking addiction treatment won’t result in disclosure across healthcare systems.
Compliance Risk: Non-compliant entities face immediate OCR audit risk. Healthcare organizations that haven’t updated their NPP, revised information-sharing policies, or trained staff on new SUD record handling face potential enforcement action starting today.
Operational Impact: Health information exchanges, EHR platforms, and integrated delivery networks must implement technical controls separating SUD records from general patient records in ways that comply with the enhanced consent requirements.
India’s BIRAC-RDI Fund: $240M for Domestic Biopharma
What Happened: India announced a $240 million (INR 2,000 crore) fund through BIRAC (Biotechnology Industry Research Assistance Council) to accelerate domestic biotech innovation, specifically targeting manufacturing technologies at Technology Readiness Levels 4-9 (proof-of-concept through full production scale). Phase 1 submissions close March 31, 2026.
Strategic Context: The fund represents India’s coordinated push to capture pharmaceutical manufacturing reshoring away from China. As Western pharmaceutical companies implement “China+1” diversification strategies following COVID-19 supply chain disruptions and geopolitical concerns, India is positioning itself as the primary alternative.
What BioAsia 2026 Signals:
The timing of this announcement alongside BioAsia 2026 in Hyderabad—India’s premier biopharma industry conference—is deliberate. Major companies including Novartis and Eli Lilly are attending with manufacturing capacity in focus.
Eli Lilly’s India Interest: Lilly has been expanding Indian manufacturing partnerships partly driven by the massive scale-up required for GLP-1 therapies. India’s established contract development and manufacturing (CDMO) capabilities in injectable biologics align with Lilly’s production needs.
Novartis’s India Play: Novartis has longstanding Indian manufacturing relationships and is exploring expansion for both branded and generic products targeting emerging markets.
Investment Implications: Indian CDMO companies and biopharma manufacturers with capacity to absorb Western reshoring demand are positioned to benefit:
- Divi’s Laboratories: API manufacturing scale
- Biocon Biologics: Biosimilar production capabilities
- Lonza India, Samsung Biologics (Indian facilities): Fill/finish capacity
The China+1 Thesis Acceleration: Each major pharmaceutical company that publicly commits to Indian manufacturing capacity reinforces the structural shift. Watch for specific capacity announcements from Lilly and Novartis during BioAsia for confirmation of timeline and investment magnitude.
Strategic Themes
Nephrology as the “Safe Haven” Sector
Two major Phase 3 wins in kidney disease within weeks—Novartis atrasentan (IgA nephropathy) and now Roche Gazyva (PMN)—confirm nephrology as one of the most productive clinical development areas of 2026.
Why Nephrology Works Right Now:
Regulatory alignment: Kidney function endpoints (eGFR, proteinuria, complete remission) are clinically meaningful and align with FDA’s current preference for robust outcomes over biomarkers.
Pricing environment: CMS and policymakers have focused drug pricing pressure on cardiovascular and diabetes medications. Rare kidney diseases remain largely exempt from the political attention that drives negotiation under the Inflation Reduction Act.
Unmet need depth: Most autoimmune kidney diseases have inadequate treatment options. Physicians are motivated to adopt effective new therapies quickly.
Patient population characteristics: Rare to ultra-rare disease sizing justifies orphan drug economics and premium pricing without the market access battles seen in larger indications.
Companies Positioned in Nephrology:
- Roche: Gazyva (PMN, lupus nephritis), plus earlier pipeline
- Novartis: Atrasentan (IgA nephropathy), Fabhalta (PNH with renal implications)
- Travere Therapeutics: Sparsentan (IgA nephropathy, FSGS)
- Calliditas Therapeutics: Tarpeyo (IgA nephropathy)
- Chinook/Novartis: ATLAS program
- Maze Therapeutics: APOL1 inhibitor for genetic kidney disease
The Investment Thesis: Broad diversified exposure to nephrology pipeline carries lower binary risk than single-asset bets, with multiple shots on goal across autoimmune, genetic, and metabolic kidney diseases.
The Acquisition Premium Debate: Pre-Data vs. Post-Data
Sanofi’s reported pre-data bid for Ocular Therapeutix raises a recurring strategic question in biotech M&A: when should acquirers move?
Pre-Data Acquisition Arguments:
- Lower cost: Before successful data inflates valuations
- Certainty: Avoids competitive bidding war post-positive readout
- Strategic lock-in: Prevents competitor from acquiring the asset
Post-Data Acquisition Arguments:
- Risk reduction: Only pays premium for validated asset
- Better diligence: Full data enables accurate valuation
- Leverage: Can walk away if data disappoints
Historical Outcomes Analysis:
Pre-data acquisitions that succeeded (AstraZeneca buying Alexion before many late-stage readouts) created enormous shareholder value for acquirers. Pre-data acquisitions that failed (multiple high-profile examples of acquired assets failing in pivotal trials) created massive write-downs.
The Sanofi-Specific Risk: Unlike acquisitions of diversified pipelines (where some assets will succeed even if others fail), AXPAXLI is effectively Ocular Therapeutix’s primary near-term value driver. Sanofi is making a concentrated bet on a single data readout. The $22-28/share range implies significant risk premium that only makes sense if internal conviction is high.
Frequently Asked Questions
Q: What is primary membranous nephropathy and why does it matter?
Primary membranous nephropathy is an autoimmune kidney disease where the immune system attacks the glomerular membrane, causing protein to leak from blood into urine. Over time, persistent proteinuria damages kidneys, and up to 30% of patients progress to kidney failure. It’s uncommon (12,000-15,000 new U.S. cases annually) but devastating when undertreated. The current standard (tacrolimus) has high relapse rates and kidney toxicity concerns. Gazyva’s ability to target the underlying B-cell pathology rather than broadly suppressing immunity represents a meaningfully different therapeutic approach.
Q: Why does Gazyva beat tacrolimus specifically?
Tacrolimus suppresses the immune system broadly without addressing the root cause—B-cells producing anti-PLA2R antibodies that attack the kidney. Gazyva depletes these B-cells directly and more completely than alternatives, with remissions that persist because the underlying autoimmune driver is eliminated rather than suppressed. When tacrolimus is discontinued, the immune system recovers and disease returns. With Gazyva-induced B-cell depletion, remissions are more durable because the offending cell population takes months to regenerate.
Q: What would Sanofi get from acquiring Ocular Therapeutix?
Beyond AXPAXLI (if successful), Ocular Therapeutix has a commercial-stage sustained-release dexamethasone product (Dextenza) for ocular inflammation and a pipeline including additional sustained-release ophthalmic formulations. The core strategic asset is AXPAXLI for wet AMD—if it works, Sanofi gains a potentially best-in-class wet AMD therapy positioned against the dominant Eylea franchise. The company also brings drug delivery expertise in intravitreal implants applicable across multiple eye conditions.
Q: How does a trispecific antibody work compared to combination therapy?
A combination of three separate drugs (e.g., PD-1 inhibitor + VEGF inhibitor + CTLA-4 inhibitor) distributes each drug throughout the body, causing systemic immune activation that drives toxicity in off-target organs. A trispecific antibody combines all three mechanisms in one molecule that ideally concentrates at the tumor site. The goal is achieving equivalent anti-tumor activity with less systemic toxicity. Additionally, the tumor microenvironment receives coordinated simultaneous blockade of all three pathways rather than sequential or partial overlap of three separate drugs.
Q: Why is India’s BIRAC fund strategically important now?
The pharmaceutical industry learned from COVID-19 that geographic concentration of manufacturing creates systemic supply risk. China dominates API production (60-80% of global supply for many categories), making diversification a strategic imperative rather than just a cost optimization exercise. India has the manufacturing expertise, regulatory framework (FDA-inspected facilities), and cost structure to absorb reshoring demand. The $240M BIRAC fund lowers the cost and risk for Indian manufacturers to upgrade capabilities to global standards, accelerating the timeline for meaningful “China+1” production volumes.
Q: Does Alkermes’s Avadel acquisition make strategic sense?
Yes, with caveats. Lumryz’s once-nightly advantage over Xyrem addresses a real clinical need (patients don’t want to wake up to take a second dose), and narcolepsy is significantly underdiagnosed with room for market expansion. The $2.37 billion price is substantial for a single commercial product, requiring Lumryz to reach $400-500 million in annual sales to justify the multiple. Alkermes is betting on continued diagnosis growth and switching from twice-nightly oxybate—an achievable but not certain outcome.
Q: What should I watch at Medtronic’s earnings today?
Focus on three areas: First, Symplicity adoption—the renal denervation catheter for resistant hypertension represents a multibillion-dollar market opportunity if it achieves real-world penetration matching trial results. Second, PulseSelect performance—pulsed field ablation for atrial fibrillation is the hottest growth area in electrophysiology, and Medtronic’s ability to compete with Abbott and Johnson & Johnson here will define near-term growth. Third, margin trajectory—Medtronic has guided toward improving operating margins; any deviation signals operational challenges.
Q: What is the significance of Vanda’s Bysanti PDUFA this weekend?
Bysanti (tradipitant) is a neurokinin-1 receptor antagonist being evaluated for bipolar I disorder and schizophrenia. The PDUFA on February 21 is a binary catalyst for a small company (Vanda) with limited pipeline beyond this asset. If approved, it adds a novel mechanism to psychiatric treatment—relevant given ongoing concerns about metabolic and weight side effects with current antipsychotics. If rejected, Vanda faces significant near-term challenges. The outcome also signals FDA’s receptiveness to novel psychiatric mechanisms versus established dopamine/serotonin-focused drugs.
Stay Ahead of the Market
Today’s SOL-1 data readout from Ocular Therapeutix moves at market open. By the time most readers see the headline, institutional desks will have already repositioned.
BioMed Nexus Daily — Free
Join 85,000+ healthcare professionals
The essential morning briefing for biotech, medtech, and pharma. Delivered before market open, every trading day.
đź”’ Today’s Pro Brief Preview:
Today’s Pro Brief models whether Sanofi’s reported $22-28/share bid reflects genuine data confidence or competitive desperation—and what the SOL-1 outcome means for ophthalmology M&A pipelines at Roche, Novartis, and AbbVie. Also inside: why Roche and Novartis’s consecutive nephrology wins confirm the “safe haven” thesis, and how India’s BIRAC fund creates a specific supply chain arbitrage opportunity as Lilly scales orforglipron production.
Pro members get scenario modeling, probability-weighted outcomes, and positioning frameworks before the market prices them in.
Access full institutional analysis →
BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma. This analysis is for informational purposes and does not constitute investment advice.
